TGF-β: A balancing act

International Reviews of Immunology

Volumn 16, Issue 5-6, 1998, Pages 553-580

  McCartney Francis, N L ^a   Frazier Jessen, M ^a   Wahl, S M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Autoimmunity; Inflammation; Knockouts; Transforming growth factor ; Transgenics; Wound healing

Indexed keywords

EID: 0031831154     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830189809043009     Document Type: Article

References (118)

1. McCartney-Francis, N.L. and Wahl, S.M. Transforming growth factor β: a matter of life and death. J. Leukoc. Biol. 55 (1994) 401-409.
2. Roberts, A.B. and Sporn, M.B. Transforming growth factor-β. In: The Molecular and Cellular Biology of Wound Repair 1996, edited by Clark, R.A.F. New York: Plenum Press, pp. 275-308.
3. Lawrence, D.A. Transforming growth factor-β: a general review. Eur. Cytokine Netw. 7 (1996) 363-374.
4. Shah, M., Foreman, D.M. and Ferguson, M.W.J. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108 (1995) 15-17.
5. Nunes, I., Munger, J.S., Harpel, J.G., Nagano, Y., Shapiro, R.L., Gleizes, P.-E. and Rifkin, D.B. Structure and activation of the large latent transforming growth factor-β complex. Intl. J. Obes. 20 (1996) S4-S8.
6. Miyazono, K., Ichijo, H. and Heldin, C.-H. Transforming growth factor-β: latent forms, binding proteins and receptors. Growth Factors 8 (1993) 11-22.
7. Grainger, D.J., Kemp, P.R., Liu, A.C., Lawn, R.M. and Metcalfe, J.C. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 370 (1994) 460-462.
8. Grainger, D.J., Kemp, P.R., Metcalfe, J.C., Liu, A.C., Lawn, R.M., Grace, A.A., Williams, N.R., Schofield, P.M. and Chauhan, A. Active transforming growth factor β is depressed five fold in patients with coronary artery disease. Nature Med. 1 (1995) 74-79.
9. Altman, D.J., Schneider, S.L., Thompson, D.A., Cheng, H.L. and Tomasi, T.B. A transforming growth factor-β2 (TGF-β2)-like immunosuppressive factor in amniotic fluid and localization of TGF-β2 mRNA in the pregnant uterus. J. Exp. Med. 172 (1990) 1391-1401.
10. Schultz-Cherry, S., Chen, H., Mosher, D.F., Misenheimer, T.M , Krutzch, H.C., Roberts, D.D. and Murphy-Ulrich, J.E. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 270 (1995) 7304-7310.
11. Kim, S.-J., Romeo, D., Yoo, Y.D. and Park, K. Transforming growth factor-β: expression in normal and pathological conditions. Horm. Res. 42 (1994) 5-8.
12. Yoo, Y.D., Ueda, H., Park, K., Flanders, K.C., Lee, Y.I., Jay, G. and Kim, S.-J. Regulation of transforming growth factor-β1 expression by the hepatitis B virus (HBV) X transactivator. J. Clin. Invest. 97 (1996) 388-395.
13. Yoo, Y.D., Chiou, C.J., Choi, K.S., Yi, Y., Michelson, S., Kim, S., Hayward, G.S. and Kim, S.J. The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta-1 gene through an Egr-1 binding site. J. Virol. 70 (1996) 7062-7070.
14. Dey, B.R., Sukhatme, V.P., Roberts, A.B., Sporn, M.B., Rauscher III, F.J. and Kim, S.-J. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol. Endocrinol. 8 (1994) 595-602.
15. Kim, S.J., Park, K., Rudkin, B.B., Dey, B.R., Sporn, M.B. and Roberts, A.B. Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC12 cells. J. Biol. Chem. 269 (1994) 3739-3744.
16. Nørgaard, P., Hougaard, S., Poulsen, H.S. and Spang-Thomsen, M. Transforming growth factor β and cancer. Cancer Treat. Rev. 21 (1995) 367-403.
17. Yingling, J.M., Wang, X.-F. and Bassing, C.H. Signaling by the transforming growth factor-β receptors. Biochim. Biophys. Acta. 1242 (1995) 115-136.
18. López-Casillas, F., Wrana, J.L. and Massagué, J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell 73 (1993) 1435-1444.
19. Cheifetz, S., Bellon, T., Calés, C., Vera, S., Bernabeu, C., Massagué, J. and Letarte, M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. Biol. Chem. 267 (1992) 19027-19030.
20. Wrana, J.L., Attisano, L., Wieser, R., Ventura, F. and Massague, J. Mechanism of activation of the TGF-β receptor. Nature 370 (1994) 341-347.
21. Attisano, L., Wrana, J.L., Montalvo, E. and Massague, J. Activation of signaling by the activin receptor complex. Mol. Cell. Biol. 16 (1996) 1066-1073.
22. Wieser, R., Wrana, J.L. and Massague, J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 14 (1995) 2199-2208.
23. Wang, T., Li, B.-Y., Danielson, P.D., Shah, P.C., Rockwell, S., Lechleider, R.J., Martin, J., Manganaro, T. and Donahoe, P.K. The immunopbilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell 86 (1996) 435-444.
24. Wang, T., Danielson, P.D., Li, B., Shah, P.C., Kim, S.D. and Donahoe, P.K. p21Ras farnesyltransferase-α subunit in TGFβ and activin signaling. Science 271 (1996) 1120-1122.
25. Kawabata, M., Inamura, T., Miyazono, K., Engel, M.E. and Moses, H.L. Interaction of the transforming growth factor-β type I receptor with farnesyltransferase-α. J. Biol. Chem. 270 (1995) 29628-29631.
26. Chen, R.H., Miettinen, P.J., Maruoka, E.M., Choy, L. and Derynck, R. A WD-domain protein that is associated with, and phosphorylated by, the type II TGF-beta receptor. Nature 377 (1995) 548-552.
27. Ventura, F., Liu, F., Doody, J and Massagué, J. Interaction of transforming growth factor-β receptor I with farnesyl-protein transferase-α in yeast and mammalian cells. J. Biol. Chem. 271 (1996) 13931-13934.
28. Yamaguchi, K., Shirakabe, K., Shibuya, H., Irie, K., Oishi, I , Ueno, N., Taniguchi, T., Nishida, E. and Matsumoto, K. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270 (1995) 2008-2011.
29. Massagué, J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 85 (1996) 947-950.
30. Zhang, Y., Feng, X.-H., Wu, R.-Y. and Derynck, R. Mad homologues synergize as effectors of the TGF-β response. Nature 383 (1996) 168-172.
31. Macias-Silva, M., Abdollah, S., Hoodless, P.A., Pirone, R., Attisano, L. and Wrana, J.L. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87 (1996) 1215-1224.
32. Lagna, G., Hata, A., Hemmati-Brivanlou, A. and Massague, J. Partnership between DPC4 and SMAD proteins in TGF-β signaling pathways. Nature 383 (1996) 832-836.
33. Hahn, S.A., Schutte, M., Hogue, A.T.M.S., Moskaluk, C.A., da Costa, L.T., Rozenblum, E., Weinstein, C.L., Fischer, A., Yeo, C.J., Hruban, R.H. and Kern, S.E. DPC4, A candidate tumor suppressor gene at human chromosome 18q21.1. Science 271 (1996) 350-353.
34. Liu, F., Hata, A., Baker, J.C., Doody, J., Cárcamo, J., Harland, R.M. and Massagué, J. A human MAD protein acting as a BMP-regulated transcriptional activator. Nature 381 (1996) 620-623.
35. Roberts, A.B. and Sporn, M.B. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol. Reprod. Dev. 32 (1992) 91-98.
36. Dickson, M.C., Martin, J.S., Cousins, F.M., Kulkarni, A.B., Karlsson, S. and Akhurst, R.J. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 121 (1995) 1845-1854.
37. Bonyadi, M., Rusholme, S.A.B., Cousins, F.M., Su, H.C., Biron, C.A., Farrall, M. and Akhurst, R.J. Mapping of a major genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nature Genet. 15 (1997) 207-211.
38. Oshima, M., Oshima, H. and Taketo, M.M. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Devel. Biol. 179 (1996) 297-302.
39. Letterio, J.J., Geiser, A.G., Kulkarni, A.B., Roche, N.S., Sporn, M.B. and Roberts, A.B. Maternal rescue of transforming growth factor-β1 null mice. Science 264 (1994) 1936-1938.
40. Diebold, R.J., Eis, M.J., Yin, M., Ormsby, I., Boivin, G.P., Darrow, B.J. Saffitz, J.E. and Doetschman, T. Early-onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte mediated. Proc. Natl. Acad. Sci. USA 92 (1995) 12215-12219.
41. Kaartinen, V., Voncken, J.W., Shuler, C., Warburton, D., Bu, D., Heisterkamp, N. and Groffen, J. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction. Nature Genet. 11 (1995) 415-420.
42. Proetzel, G., Pawlowski, S.A., Wiles, M.V., Yin, M., Boivin, G.P., Howles, P.N., Ding, J., Ferguson, M.W.J. and Doetschman, T. Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet. 11 (1995) 409-414.
43. Sellheyer, K., Bickenbach, J.R., Rothnagel, J.A., Bundman, D., Longley, M.A., Krieg, T., Roche, N.S., Roberts, A.B. and Roop, D.R. Inhibition of skin development by overexpression of transforming growth factor-β1 in the epidermis Of transgenic mice. Proc. Natl. Acad. Sci. USA 90 (1993) 5237-5241.
44. Cui, W., Fowlis, D.J., Cousins, F.M., Duffie, E., Bryson, S., Balmain, A. and Akhurst, R.J. Concerted action of TGF-β1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Devel. 9 (1995) 945-955.
45. Fowlis, D.J., Cui, W., Johnson, S.A., Balmain, A. and Akhurst, R.J. Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor β1 in the skin of transgenic mice. Cell Growth Diff. 7 (1996) 679-687.
46. Jhappan, C., Geiser, A.G., Kordon, E.C., Bagheri, D., Hennighausen, L., Roberts, A.B., Smith, G.H. and Merlino, G. Targeting expression of a transforming growth factor-β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J. 12 (1993) 1835-1845.
47. Pierce, D.F. Jr., Johnson, M.D., Matsui, Y., Robinson, S.D., Gold, L.I., Purchio, A.F., Daniel, C.W., Hogan, B.L.M. and Moses, H.L. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Devel. 7 (1993) 2308-2317.
48. Lee, M.-S., Gu, D., Feng, L., Curriden, S., Arnush, M., Krahl, T., Gurushanthaiah, D., Wilson, C., Loskutoff, D.L., Fox, H. and Sarvetnick, N. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-β1. Am. J. Pathol. 147 (1995) 42-52.
49. Sanvito, F., Nichols, A., Herrera, P -L., Huarte, J., Wohlwend, A., Vassalli, J.-D. and Orci, L. TGF-β1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-α, triggers insulin-dependent diabetes. Biochem. Biophys. Res. Commun. 217 (1995) 1279-1288.
50. Wyss-Coray, T., Feng, L., Masliah, E., Ruppe, M.D., Lee, H.S., Toggas, S.M., Rockenstein, E.M. and Mucke, L. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am. J. Pathol. 147 (1995) 53-67.
51. Galbreath, E., Kim, S.-J., Park, K., Brenner, M. and Messing, A. Overexpression of TGFβ1 in the central nervous system of transgenic mice results in hydrocephalus. J. Neuropathol. Exp. Neurol. 54 (1995) 339-349.
52. Sanderson, N., Factor, V., Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., Roberts, A.B. and Sporn, M.B., Thorgeirsson, S.S. Hepatic expression of mature transforming growth factor-β1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA 92 (1995) 2572-2576.
53. Zhou, L., Dey, C.R., Wert, S.E. and Whitsett, J.A. Arrested lung morphogenesis in transgenic mice bearing an SP-C-TGF-beta 1 chimeric gene. Dev. Biol. 175 (1996) 227-238.
54. Erlebacher, A. and Derynck, R. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell. Biol. 132 (1996) 195-210.
55. Alexandrow, M.G. and Moses, H.L. Transforming growth factor β and cell cycle regulation. Cancer Research 55 (1995) 1452-1457.
56. Schwarz, J.K., Bassing, C.H., Kovesdi, I., Datto, M.B., Blazing, M., George, S., Wang, X.-F. and Nevins, J.R. Expression of the E2F1 transcription factor overcomes type β transforming growth factor-mediated growth suppression. Proc. Natl. Acad. Sci. USA 92 (1995) 483-487.
57. Glick, A.B., Kulkarni, A.B., Tennenbaum, T., Hennings, H., Flanders, K.C., O'Reilly, M., Sporn, M.B., Karlsson, S. and Yuspa, S.H. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc. Natl. Acad. Sci. USA 90 (1993) 6076-6080.
58. Markowitz, S.D. and Roberts, A.B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cyt. Growth Fact. Rev. 7 (1996) 93-102.
59. Sun, L., Wu, G., Willson, J.K.V., Zborowska, E., Yang, J., Rajkarunanayake, I., Wang, J., Gentry, L.E., Wang, X. and Brittain, M.G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 269 (1994) 26449-26455.
60. Wang, J., Han, W., Zborowska, E , Liang, J., Wang, X., Willson, J.K.V., Sun, L. and Brattain, M.G. Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells J. Biol. Chem. 271 (1996) 17366-17371.
61. Goyette, M.C., Cho, K., Fasching, C.L., Levy, D.B., Kinzler, K.W., Paraskeva, C., Vogelstein, B. and Stanbridge, E.J. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol. Cell. Biol. 12 (1992) 1387-1395.
62. Eppert, K., Scherer, S.W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.-C., Bapat, B., Gallinger, S., Andrulis, I.L., Thomsen, G.H., Wrana, J.L. and Attisano, L. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86 (1996) 543-552.
63. Arteaga, C.L., Coffey, R.J.Jr., Dugger, T.C., McCutchen, C.M., Moses, H.L. and Lyons, R.M. Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: evidence for negative autocrine regulation by transforming growth factor β. Cell Growth & Differ. 1 (1990) 367-374.
64. Wu, S., Theodorescu, D., Kerbel, R., Willson, J.K.V , Mulder, K.M., Humphrey, L.E. and Brattain, M.G. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an anti-sense expression vector. J. Cell. Biol. 116 (1992) 187-196.
65. Pierce, D.F. Jr., Gorska, A.E., Chytil, A., Meise, K.S., Page, D.L. and Coffey, R.L. Jr., Moses, H.L. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc. Natl. Acad. Sci. USA 92 (1995) 4254-4258.
66. Cui, W., Fowlis, D.J., Bryson, S., Duffie, E., Ireland, H., Balmain, A. and Akhurst, R.J. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86 (1996) 531-542.
67. Glick, A.B., Lee, M.M., Darwiche, N., Kulkarni, A.B., Karlsson, S. and Yuspa, S.H. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Devel. 8 (1994) 2429-2440.
68. Glick, A.B., Weinberg, W.C., Wu, I.H., Quan, W. and Yuspa, S.H. Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res, 56 (1996) 3645-3650.
69. Christ, M., McCartney-Francis, N.L , Kulkarni, A.B., Ward, J.M., Mizel, D.E., Mackall, C.L., Gress, R.E., Hines, K.L., Tian, H., Karlsson, S. and Wahl, S.M. Immune dysregulation in TGF-β1 -deficient mice. J. Immunol. 153 (1994) 1936-1946.
70. Boivin, G.P., O'Toole, B.A., Ormsby, I.E., Diebold, R.J., Eis, M.J., Doetschman, T. and Kier, A.B. Onset and progression of pathological lesions in transforming growth factor-β1-deficient mice. Am. J. Pathol. 146 (1995) 276-288.
71. Letterio, J.J., Geiser, A.G., Kulkarni, A.B., Dang, H., Kong, L., Nakabayashi, T., Mackall, C.L., Gress, R.E. and Roberts, A.B. Autoimmunity associated with TGF-β1 deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 98 (1996) 2109-2119.
72. Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., Allen, R., Sidman, C., Proetzel, B., Calvin, D., Annunziata, N. and Doetschman, T. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359 (1992) 693-699.
73. Shull, M.M., Kier, A.B., Diebold, R.J., Yin, M. and Doetschman, T. The importance of transforming growth factor β1 in immunological homeostasis, as revealed by gene ablation in mice. In: Overexpression and knockout of cytokines in transgenic mice 1994. London: Academic Press, 135-159.
74. McCartney-Francis, N.L., Mizel, D.E., Redman, R.S., Frazier-Jessen, M., Panek, R.B., Kulkarni, A.B., Ward, J.M., McCarthy, J.B. and Wahl, S.M. Autoimmune Sjögren's-like lesions in salivary glands of TGF-β1-deficient mice are inhibited by adhesion-blocking peptides. J. Immunol. 157 (1996) 1306-1312.
75. Borkowski, T.A., Letterio, J.J , Farr, A.G. and Udey, M.C. A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor βI null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 184 (1996) 2417-2422.
76. Arsura, M., Wu, M. and Sonenshein, G.E. TGF-β1 inhibits NF-κB/Rel activity inducing apoptosis of B cells: transcriptional activation of IκBα. Immunity 5 (1996) 31-40.
77. Wahl, S.M. Transforming growth factor α: the good, the bad, and the ugly. J. Exp. Med. 180 (1994) 1587-1590.
78. Wahl, S.M., Hunt, D.A., Wakefield, L., McCartney-Francis, N., Wahl, L.M., Roberts, A.B. and Sporn, M.B. Transforming growth factor beta (TGF-β) induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA 84 (1987) 5788-5792.
79. Wahl, S.M., Allen, J.B., Weeks, B.S., Wong, H.L. and Klotman, P.E. Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc. Natl. Acad. Sci. USA 90 (1993) 4577-4581.
80. Brandes, M.E., Wakefield, L.M. and Wahl, S.M. Modulation of monocyte type I TGF-β receptors by inflammatory stimuli. J. Biol. Chem. 266 (1991) 19697-19703.
81. Kulkarni, A.B., Huh, C.-H., Becker, D., Geiser, A., Lyght, M., Flanders, K.C., Roberts, A.B., Sporn, M.B., Ward, J.M. and Karlsson, S. Transforming growth factor-β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90 (1993) 770-774.
82. Kulkarni, A.B., Ward, J.M., Yaswen, L., Mackall, C.L., Bauer, S.R., Huh, C.-G., Gress, R.E. and Karlsson, S. Transforming growth factor-β1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 146 (1995) 1-12.
83. McCartney-Francis, N.L., Mizel, D.E., Frazier-Jessen, M., Kulkarni, A.B., McCarthy, J.B. and Wahl, S.M. Lacrimal gland inflammation is responsible for ocular pathology in TGF-β1 null mice. Submitted.
84. Dang, H., Geiser, A.G., Letterio, J.J., Nakabayashi, T., Kong, L., Fernandes, G. and Talal, N. SLE-like auto antibodies and Sjögren's syndrome-like lymphoproliferation in TGF-β knockout mice. J. Immunol. 155 (1995) 3205-3212.
85. Yaswen, L., Kulkarni, A.B., Fredrickson, T., Mittleman, B., Schiffmann, R., Payne, S., Longenecker, G., Mozes, E. and Karlsson, S. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse. Blood 87 (1996) 1439-1445.
86. Geiser, A.G., Letterio, J.J., Kulkarni, A.B., Karlsson, S., Roberts, A.B. and Sporn, M.B. TGF-β1 controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatability antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl. Acad. Sci. USA 90 (1993) 9944-9948.
87. Frazier-Jessen, M., McCartney-Francis, N. and Wahl, S.M. Transforming growth factor-β: a cytokine paradigm. In: Handbook of Immune Modulating Agents 1997, edited by Kresina, T. New York: Marcel Dekker, in press.
88. Stavnezer, J. Regulation of antibody production and class scitching by TGF-β. J. Immunol. 155 (1995) 1647-1651.
89. Hines, K.L., Kulkarni, A.B., McCarthy, J.B., Tien, H., Ward, J.M., Christ, M., McCartney-Francis, N.L., Furcht, L.T., Karlsson, S. and Wahl, S.M. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in TGF-β1 knockout mice. Proc. Natl. Acad. Sci. USA 91 (1994) 5187-5191.
90. Mossman, T.R. and Sad, S. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol. Today 17 (1996) 138-146.
91. Nicholson, L.B. and Kuchroo, V.K. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr. Opin. Immunol. 8 (1996) 837-842.
92. + T cells. J. Exp. Med. 183 (1996) 2669-2674.
93. + cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Diabetes 45 (1996) 71-78.
94. Vodovotz, Y. and Bogdan, C. Control of nitric oxide synthase expression by transforming growth factor-β: implications for homeostasis. Prog. Growth Factors Res. 5 (1994) 341-351.
95. Vodovotz, Y., Geiser, A.G., Chesler, L., Letterio, J.J., Campbell, A., Lucia, M.S., Sporn, M.B., and Roberts, A.B. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor β1 null mouse. J. Exp. Med. 183 (1996) 2337-2342.
96. McCallion, R.L. and Ferguson, M.W.J. Fetal wound healing and the development of antiscarring therapies for adult wound healing. In: The Molecular and Cellular Biology of Wound Repair 1996, edited by Clark, R.A.F. New York: Plenum Press, pp. 561-600.
97. Frank, S., Madlener, M. and Werner, S. Transforming growth factors β1, β2, and β3 and their receptors are differentially regulated during normal and impaired wound healing. J. Biol. Chem. 271 (1996) 10188-10193.
98. Brown, R.L., Ormsby, I., Doetschman, T.C. and Greenhalgh, D.G. Wound healing in the transforming growth factor-β1-deficient mouse. Wound Rep. Reg. 3 (1995) 25-36.
99. Letterio, J.J. and Roberts, A.B. Transforming growth factor-β1-deficient mice: identification of isoform-specific activities in vivo. J. Leuk. Biol. 59 (1996) 769-774.
100. Border, W.A. and Noble, N.A. Transforming growth factor β in tissue fibrosis. N. Eng. J. Med. 331 (1994) 1286-1292.
101. Kopp, J.B., Factor, V.M., Mozes, M., Nagy, P., Sanderson, N., Böttinger, E.P., Klotman, P.E. and Thorgeirsson, S.S. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab. Invest. 74 (1996) 991-1003.
102. Wahl, S.M., Frazier-Jessen, M., Jin, W.W., Kopp, J.B., Sher, A. and Cheever, A.W. Cytokine regulation of schistosome-induced granuloma and fibrosis. Kidney Int. 51 (1997) 1370-1375.
103. Border, W.A., Noble, N.A., Yamamoto, T., Harper, J.R., Yamaguchi, Y., Pierschbacher, M.D. and Ruoslahti, E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 360 (1992) 361-364.
104. Isaka, Y., Brees, D.K., Ikegaya, K., Kaneda, Y., Imai, E., Noble, N.A. and Border, W.A. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. 2 (1996) 418-423.
105. Imai, E., Isaka, Y., Akagi, Y., Arai, M., Moriyama, T., Takenaka, M., Kaneko, T., Horio, M., Ando, A., Orita, Y., Kaneda, Y., Ueda, N. and Kamada, T. Application of antisense oligodeoxynucleotides (ODNs) for the intervention of kidney disease. In: Cytokines, Growth Factors and Macrophages 1996, edited by Koide H. and Ichikawa I. Basel: Karger, pp. 86-93.
106. Kitamura, M., Burton, S., English, J., Kawachi, H. and Fine, L.G. Transfer of a mutated gene encoding active transforming growth factor-β1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int. 48 (1995) 1747-1757.
107. Isaka, Y., Fujiwara, Y., Ueda, N., Kaneda, Y., Kamada, T. and Imai, E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. 92 (1993) 2597-2601.
108. Choi, B.-M., Kwak, H.-J., Jun, C.-D., Park, S.-D., Kim, K.-Y., Kim, H.-R. and Chung, H.-T. Control of scarring in adult wounds using antisense transforming growth factor-β1 oligodeoxynucleotides. Immunol. Cell Biol. 74 (1996) 144-150.
109. Benn, S.I., Whitsitt, J.S., Broadley, K.M., Nanney, L.B., Perkins, D., He, L., Patel, M., Morgan, J.R., Swain, W.F. and Davidson, J.M. Particle-mediated gene transfer with transforming growth factor-β1 cDNAs enhances wound repair in rat skin. J. Clin. Invest. 98 (1996) 2894-2902.
110. Grainger, D.J., Witchell, C.M. and Metcalfe, J.C. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nature Med. 1 (1995) 1067-1072.
111. Brandes, M.E., Allen, J.B., Ogawa, Y. and Wahl, S.M. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J. Clin. Invest. 87 (1991) 1108-1113.
112. Weiner, H.L. Oral tolerance. Proc. Natl. Acad. Sci. USA 91 (1994) 10762-10765.
113. Chen, Y., Kuchroo, V.K., Inobe, J .-I., Hafler, D.A. and Weiner, H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265 (1994) 1237-1240.
114. Weiner, H.L., Mackin, G.A., Matsui, M., Orav, E.J., Khoury, S.J., Dawson, D.M. and Hafler, D.A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259 (1993) 1321-1324.
115. Trentham, D.E., Dynesius-Trentham, R.A., Orav, E.J., Combitchi, D., Lorenzo, C., Sewall, K.L., Hafler, D.A. and Weiner, H.L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993) 1727-1730.
116. McFarland, H.F. Complexities in the treatment of autoimmune disease. Science 274 (1996) 2037-2038.
117. Fakhrai, H., Dorigo, O., Shawler, D.L., Lin, H., Mercola, D., Black, K.L., Royston, I. and Sobol, R.E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 93 (1996) 2909-2914.
118. Grainger, D.J. and Metcalfe, J.C. Tamoxifen: teaching an old drug new tricks? Nature Med. 2 (1996) 381-385.